What infections has Cosentyx (secukinumab) been linked to?
Cosentyx is associated with an increased risk of certain infections, particularly common respiratory and other mucosal infections, because it works by blocking IL-17A, a pathway involved in normal immune defense at mucosal surfaces. [1]
Are there specific infection types people report or get?
Commonly reported infection types for IL-17 blockers include:
- Upper respiratory tract infections (such as colds)
- Other respiratory infections
- Fungal infections, especially mucocutaneous candidiasis (yeast infections in the mouth/throat) [1][2]
Are serious infections a concern?
Serious infections can occur with Cosentyx, as with other immune-modulating therapies. People are typically advised to seek medical care promptly if they develop fever, worsening symptoms, or signs of an infection while using Cosentyx. [1]
Who is at higher risk of infections on Cosentyx?
Risk is generally higher in people with factors such as:
- Active or recurrent infections
- Conditions that weaken the immune system
- Use of other immunosuppressive medicines [1]
What should patients do if they suspect an infection?
Patients are generally advised to contact their clinician if they suspect an infection while on Cosentyx, especially if symptoms are severe or not improving. Clinicians may consider holding treatment depending on the type and severity of the infection. [1]
How does Cosentyx compare with other biologics on infection risk?
Infection risk is a known class issue across biologics that affect immune pathways. For IL-17 blockade specifically, mucocutaneous fungal infections (like yeast infections) are a key concern, along with respiratory infections. [1][2]
Sources
- Cosentyx (secukinumab) Prescribing Information – infection warnings and adverse reactions
- European Medicines Agency (EMA) Cosentyx product information – infections and fungal risk